Literature DB >> 28611981

The Clinical Significance of Alpha-Fetoprotein mRNAs in Patients with Hepatocellular Carcinoma.

Shogo Kobayashi1, Akira Tomokuni1, Hidenori Takahashi1, Hirofumi Akita1, Keijiro Sugimura1, Norikatsu Miyoshi1, Jeong Ho Moon1, Masayoshi Yasui1, Takeshi Omori1, Masayuki Ohue1, Yoshiyuki Fujiwara1, Masahiko Yano1, Masato Sakon1.   

Abstract

BACKGROUND/AIMS: Alpha-fetoprotein (AFP) mRNA-expressing cells are candidates for circulating tumor cells in hepatocellular carcinoma. We analyzed portal vein blood, peripheral blood, and peritoneal lavage samples to detect the presence of AFP mRNA-expressing cells, and explored their relationship with metastasis.
METHODS: We measured the AFP mRNA expression in 112 sets of portal vein and peripheral blood samples and 61 peritoneal lavage samples that had been obtained during surgery. We estimated the change in the positive ratio of patients with AFP mRNA, the associated background factors, and the rate of recurrence.
RESULTS: The change in AFP mRNA positivity in the peripheral blood specimens was remarkable, while that in the portal vein blood and peritoneal lavage samples was similar during hepatectomy. Tumor location was the only factor associated with AFP mRNA positivity. The rate of recurrence was higher in the patients who were positive for AFP mRNA than in those who were negative 9-24 months after hepatectomy. During this limited period, the recurrence rate in the AFP mRNA-positive cases was significantly higher than that in the AFP mRNA-negative cases (p = 0.0472). Postoperative AFP mRNA positivity was not related to very early recurrence (0-9 months) or multicentric liver carcinogenesis (>24 months).
CONCLUSION: AFP mRNA positivity in the peripheral blood was elevated after hepatectomy, and the elevation depended on the tumor location. AFP mRNA positivity might contribute to recurrence-free survival 9-24 months after hepatectomy.

Entities:  

Keywords:  Alpha-fetoprotein; Hepatectomy; Hepatocellular carcinoma

Year:  2017        PMID: 28611981      PMCID: PMC5465674          DOI: 10.1159/000455955

Source DB:  PubMed          Journal:  Gastrointest Tumors        ISSN: 2296-3774


  25 in total

1.  Long-term results of laparoscopic hepatectomy versus open hepatectomy for hepatocellular carcinoma: a case-matched analysis.

Authors:  Kit Fai Lee; Ching Ning Chong; Jeff Wong; Yue Sun Cheung; John Wong; Paul Lai
Journal:  World J Surg       Date:  2011-10       Impact factor: 3.352

2.  Hepatectomy based on the tumor hemodynamics for hepatocellular carcinoma: a comparison among the hybrid and pure laparoscopic procedures and open surgery.

Authors:  Shogo Kobayashi; Hiroaki Nagano; Shigeru Marubashi; Koichi Kawamoto; Hiroshi Wada; Hidetoshi Eguchi; Masahiro Tanemura; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  Surg Endosc       Date:  2012-08-31       Impact factor: 4.584

3.  Detection of isolated disseminated tumor cells in bone marrow and blood samples of patients with hepatocellular carcinoma.

Authors:  P Kienle; J Weitz; R Klaes; M Koch; A Benner; T Lehnert; C Herfarth; M von Knebel Doeberitz
Journal:  Arch Surg       Date:  2000-02

4.  Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves.

Authors:  M Sakon; K Umeshita; H Nagano; H Eguchi; S Kishimoto; A Miyamoto; S Ohshima; K Dono; S Nakamori; M Gotoh; M Monden
Journal:  Arch Surg       Date:  2000-12

5.  Circulating messenger RNA of alpha-fetoprotein: a possible risk factor of recurrence after resection of hepatocellular carcinoma.

Authors:  Kuo-Shyang Jeng; I-Shyan Sheen; Yi-Chun Tsai
Journal:  Arch Surg       Date:  2004-10

6.  Clinical significance of alpha-fetoprotein mRNA in peripheral blood in liver resection for hepatocellular carcinoma.

Authors:  Shigeru Marubashi; Hiroaki Nagano; Hiroshi Wada; Shogo Kobayashi; Hidetoshi Eguchi; Yutaka Takeda; Masahiro Tanemura; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  Ann Surg Oncol       Date:  2011-02-08       Impact factor: 5.344

7.  The effects of vitamin K on the generation of des-gamma-carboxy prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.

Authors:  M Sakon; M Monden; M Gotoh; K Kobayashi; T Kanai; K Umeshita; W Endoh; T Mori
Journal:  Am J Gastroenterol       Date:  1991-03       Impact factor: 10.864

8.  Clinical application of quantitative analysis for detection of hematogenous spread of hepatocellular carcinoma by real-time PCR.

Authors:  A Miyamoto; H Nagano; M Sakon; Y Fujiwara; Y Sugita; H Eguchi; M Kondo; I Arai; O Morimoto; K Dono; K Umeshita; S Nakamori; M Monden
Journal:  Int J Oncol       Date:  2001-03       Impact factor: 5.650

9.  Laparoscopic resection for hepatocellular carcinoma: a matched-pair comparative study.

Authors:  Hadrien Tranchart; Giuseppe Di Giuro; Panagiotis Lainas; Jean Roudie; Helene Agostini; Dominique Franco; Ibrahim Dagher
Journal:  Surg Endosc       Date:  2009-11-14       Impact factor: 4.584

10.  Detection of AFP mRNA-expressing cells in the peripheral blood for prediction of HCC recurrence after living donor liver transplantation.

Authors:  Shigeru Marubashi; Keizo Dono; Hiroaki Nagano; Yukari Sugita; Tadafumi Asaoka; Naoki Hama; Atsushi Miyamoto; Yutaka Takeda; Koji Umeshita; Morito Monden
Journal:  Transpl Int       Date:  2007-04-08       Impact factor: 3.782

View more
  2 in total

1.  Assessment of Serum Tumor Markers for Predicting Ocular Metastasis in Lung Adenocarcinoma: A Retrospective Study.

Authors:  Wen-Qing Shi; Wen-Feng Liu; Biao Li; Qi Lin; Qing-Hai Li; Yu-Qing Zhang; Qing Yuan; Rong-Bin Liang; Qian-Min Ge; Yi Shao
Journal:  Dis Markers       Date:  2020-06-25       Impact factor: 3.434

2.  Short-term outcomes of open liver resection and laparoscopic liver resection: Secondary analysis of data from a multicenter prospective study (CSGO-HBP-004).

Authors:  Shogo Kobayashi; Keisuke Fukui; Yutaka Takeda; Shin Nakahira; Masanori Tsujie; Junzo Shimizu; Atsushi Miyamoto; Hidetoshi Eguchi; Hiroaki Nagano; Yuichiro Doki; Masaki Mori
Journal:  Ann Gastroenterol Surg       Date:  2017-10-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.